The collaboration will see the Chinese partner conduct pre-clinical studies to assess monoclonal antibodies (mAbs) targeting tumour-associated glycans (TaGs) that have been enhanced with the AIM-listed company's AvidiMab technology, for the treatment of cancer.
Scancell agreed a first collaboration agreement for AvidiMab in September, alongside a pipeline of TaG mAbs, with a leading antibody technology company.
The mAbs turned out by AvidiMab are different to those used successfully in other targeted cancer treatments as they target tumour-associated glycans that are associated with malignancies, with AvidiMab enhancing the ability of these mAbs to hone in on TaGs.
"As previously stated, we believe our novel AvidiMab platform and tumour associated glycan antibodies have broad partnering potential and this has been further demonstrated by today's agreement, the second in four months," said Cliff Holloway, Scancell's chief executive officer.
"This is our first collaboration in China, and we look forward to updating the market on further progress with this platform in due course."